NasdaqGM - Nasdaq Real Time Price USD

MannKind Corporation (MNKD)

4.2300

+0.0500

(+1.20%)

At close: April 26 at 4:00 PM EDT

4.2800

+0.05

(+1.18%)

After hours: April 26 at 4:45 PM EDT

MannKind Repays Certain Debt Obligations

Credit and security agreement with MidCap Financial Trust repaid in full for approximately $31.6 millionConvertible note issued to Mann Group LLC repaid in exchange for 1.5 million shares of common stock and approximately $8.9 millionTotal debt reduced since December 31, 2023 is approximately $41.8 million DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled thera

GlobeNewswire 23 days ago

MNKD
+1.20%
MannKind Corporation (NASDAQ:MNKD) down to US$1.2b market cap, but institutional owners may not be as affected after a year of 9.7% returns

Key Insights Given the large stake in the stock by institutions, MannKind's stock price might be vulnerable to their...

Simply Wall St. 25 days ago

MNKD
+1.20%
Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 28 days ago

IOVA

MNKD
+1.20%
MannKind Announces CFO Transition

Steven B. Binder announces planned retirement and is appointed Executive Vice President, Special Projects, effective April 22, 2024, through December 31, 2024Christopher Prentiss appointed Chief Financial Officer, effective April 22, 2024 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lu

GlobeNewswire last month

MNKD
+1.20%
Jim Cramer Says You Should Avoid These 11 Stocks

In this article, we will take a detailed look at Jim Cramer Says You Should Avoid These 11 Stocks. For a quick overview of such stocks, read our article Jim Cramer Says You Should Avoid These 5 Stocks. Jim Cramer in his latest program took a jab at the Department of Justice and Washington authorities in general, calling regulators […]

Insider Monkey last month

AAPL

CRK

PAA
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps

Post-meal hyperglycemia was significantly reduced by 20% with inhaled insulin compared with rapid-acting insulin delivered through MDI or insulin pumpsSubjects utilizing inhaled insulin experienced a 22% decrease in mean glucose excursions in the first two hours compared to the standard of care17-week primary endpoint results will be presented during a 90-minute symposium at the American Diabetes Association’s Scientific Sessions in June DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 11, 202

GlobeNewswire last month

MNKD
+1.20%
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8

Dr. Hirsch to present meal challenge results when switching from multiple daily injections (MDI) or insulin pumps to inhaled insulin (Afrezza® (insulin human) Inhalation Powder)DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that new clinical data from the I

GlobeNewswire last month

MNKD
+1.20%
MannKind Corporation Announces Participation at Upcoming Conferences

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it will be participating at upcoming conferences. Leerink Partners Global Biopharma Conference 2024 – Investor Meetings, Monday, March 11, 2024 Oppenheimer 34th Annual Healthcare MedTech & Services Confere

GlobeNewswire last month

MNKD
+1.20%
Analysts Just Made A Meaningful Upgrade To Their MannKind Corporation (NASDAQ:MNKD) Forecasts

Celebrations may be in order for MannKind Corporation ( NASDAQ:MNKD ) shareholders, with the analysts delivering a...

Simply Wall St. last month

MNKD
+1.20%
MannKind Full Year 2023 Earnings: Beats Expectations

MannKind ( NASDAQ:MNKD ) Full Year 2023 Results Key Financial Results Revenue: US$199.0m (up 99% from FY 2022). Net...

Simply Wall St. last month

MNKD
+1.20%
MannKind Corporation (NASDAQ:MNKD) Q4 2023 Earnings Call Transcript

MannKind Corporation (NASDAQ:MNKD) Q4 2023 Earnings Call Transcript February 27, 2024 MannKind Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to MannKind Corporation 2023 Fourth Quarter and Full Year Financial Results Earnings Call. As a […]

Insider Monkey last month

MNKD
+1.20%
Q4 2023 MannKind Corp Earnings Call

Q4 2023 MannKind Corp Earnings Call

Thomson Reuters StreetEvents last month

MNKD
+1.20%
MannKind (MNKD) Q4 2023 Earnings Call Transcript

MNKD earnings call for the period ending December 31, 2023.

Motley Fool last month

MNKD
+1.20%
Here's What Key Metrics Tell Us About MannKind (MNKD) Q4 Earnings

The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks last month

MNKD
+1.20%
MannKind (MNKD) Q4 Earnings and Revenues Surpass Estimates

MannKind (MNKD) delivered earnings and revenue surprises of 300% and 11.67%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

MNKD
+1.20%
MannKind Corp (MNKD) Reports Substantial Revenue Growth in 2023

Full Year Revenues Nearly Double as Company Advances Clinical Development

GuruFocus.com last month

MNKD
+1.20%
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update

Conference Call to Begin Today at 5:00 p.m. (ET)2023 Total revenues of $199M; +99% vs. 20224Q 2023 Total revenues of $58M; +62% vs. 20224Q 2023 Net income of $1M; Non-GAAP net income of $7M$302M of cash and cash equivalents and investments at December 31, 2023 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the quarter and full year ended December 31, 2023. “We doubled our total revenues to ne

GlobeNewswire last month

MNKD
+1.20%
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 fourth quarter and full year financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM (Eastern Time) on Tuesday, February 27, 2024. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, and Chief Financial Officer, Steven Binder. Those interested in listening to the c

GlobeNewswire 2 months ago

MNKD
+1.20%
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®

Reached enrollment goal of 305 patients living with Type 1 or Type 2 diabetesPrimary endpoint analysis expected in 4Q 2024 Data dissemination and FDA submission expected in 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it has fully enrolled 305 patients livin

GlobeNewswire 2 months ago

MNKD
+1.20%
13 Best NASDAQ Penny Stocks To Invest In

In this article, we discuss 13 best NASDAQ penny stocks to invest in. If you want to skip our discussion on the stock market, head directly to 5 Best NASDAQ Penny Stocks To Invest In. Usually, when a bear market reaches its lowest point, like the United States stock market experienced in October 2022, it […]

Insider Monkey 2 months ago

IQ

ADVWW

^GSPC

Performance Overview

Return	MNKD	S&P 500
YTD	+16.21%	+6.92%
1-Year	+8.74%	+25.26%
3-Year	-9.62%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

MannKind Corporation (MNKD)

MannKind Repays Certain Debt Obligations

MannKind Corporation (NASDAQ:MNKD) down to US$1.2b market cap, but institutional owners may not be as affected after a year of 9.7% returns

Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?

MannKind Announces CFO Transition

Jim Cramer Says You Should Avoid These 11 Stocks

INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps

MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8

MannKind Corporation Announces Participation at Upcoming Conferences

Analysts Just Made A Meaningful Upgrade To Their MannKind Corporation (NASDAQ:MNKD) Forecasts

MannKind Full Year 2023 Earnings: Beats Expectations

MannKind Corporation (NASDAQ:MNKD) Q4 2023 Earnings Call Transcript

Q4 2023 MannKind Corp Earnings Call

MannKind (MNKD) Q4 2023 Earnings Call Transcript

Here's What Key Metrics Tell Us About MannKind (MNKD) Q4 Earnings

MannKind (MNKD) Q4 Earnings and Revenues Surpass Estimates

MannKind Corp (MNKD) Reports Substantial Revenue Growth in 2023

MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update

MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024

MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®

13 Best NASDAQ Penny Stocks To Invest In

Performance Overview